Sears PS - Search Results

1

Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.

Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. Petrella LA, et al. Among authors: sears ps. Clin Infect Dis. 2012 Aug;55(3):351-7. doi: 10.1093/cid/cis430. Epub 2012 Apr 20. Clin Infect Dis. 2012. PMID: 22523271 Free PMC article. Clinical Trial.

2

Fidaxomicin inhibits spore production in Clostridium difficile.

Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Babakhani F, et al. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S162-9. doi: 10.1093/cid/cis453. Clin Infect Dis. 2012. PMID: 22752866 Free PMC article.

3

Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015.

Cheknis A, Johnson S, Chesnel L, Petrella L, Sambol S, Dale SE, Nary J, Sears P, Citron DM, Goldstein EJC, Gerding DN. Cheknis A, et al. Anaerobe. 2018 Oct;53:38-42. doi: 10.1016/j.anaerobe.2018.05.009. Epub 2018 May 26. Anaerobe. 2018. PMID: 29886050

4

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Goldstein EJ, et al. Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15. Antimicrob Agents Chemother. 2011. PMID: 21844318 Free PMC article. Clinical Trial.

5

Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.

Babakhani F, Seddon J, Sears P. Babakhani F, et al. Antimicrob Agents Chemother. 2014 May;58(5):2934-7. doi: 10.1128/AAC.02572-13. Epub 2014 Feb 18. Antimicrob Agents Chemother. 2014. PMID: 24550338 Free PMC article.

6

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Babakhani F, Gomez A, Robert N, Sears P. Babakhani F, et al. J Med Microbiol. 2011 Aug;60(Pt 8):1213-1217. doi: 10.1099/jmm.0.029470-0. Epub 2011 Feb 24. J Med Microbiol. 2011. PMID: 21349983 Free PMC article.

7

Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile.

Babakhani F, Gomez A, Robert N, Sears P. Babakhani F, et al. Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27. Antimicrob Agents Chemother. 2011. PMID: 21709084 Free PMC article.

8

Fidaxomicin inhibits toxin production in Clostridium difficile.

Babakhani F, Bouillaut L, Sears P, Sims C, Gomez A, Sonenshein AL. Babakhani F, et al. J Antimicrob Chemother. 2013 Mar;68(3):515-22. doi: 10.1093/jac/dks450. Epub 2012 Dec 2. J Antimicrob Chemother. 2013. PMID: 23208832

9

Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.

Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL. Mullane KM, et al. Among authors: sears ps. Clin Infect Dis. 2011 Sep;53(5):440-7. doi: 10.1093/cid/cir404. Clin Infect Dis. 2011. PMID: 21844027 Free PMC article.

10

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.

Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. Sears P, et al. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S116-20. doi: 10.1093/cid/cis337. Clin Infect Dis. 2012. PMID: 22752859 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page